NUDT14: A Potential Drug Target and Biomarker (G256281)

Target Name: NUDT14

NCBI ID: G256281

NUDT14

NUDT14: A Potential Drug Target and Biomarker

Nudix hydrolase 14 (NUDT14) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and lungs. It is a member of the NUDT family of enzymes that belong to the glycoside hydrolase family 14. NUDT14 is involved in the degradation of various sugar molecules, including glucose and xylose.

The discovery of NUDT14 as a potential drug target and biomarker has significant implications for the treatment of various diseases. NUDT14 has been shown to be involved in a number of important physiological processes in the body, including the regulation of blood sugar levels and the regulation of inflammation.

One of the potential benefits of targeting NUDT14 is its potential to treat type 2 diabetes. NUDT14 has been shown to play a role in the production of toxic alpha-glucosidic peptides, which have been linked to the development of type 2 diabetes. By inhibiting NUDT14 activity, researchers have found that they can reduce the production of these peptides and improve insulin sensitivity in individuals with type 2 diabetes.

Another potential application of NUDT14 is its potential as a biomarker for monitoring disease progression in individuals with pancreatic cancer. NUDT14 has been shown to be overexpressed in pancreatic cancer, which has been associated with poor prognosis. By detecting NUDT14 levels in pancreatic cancer samples, researchers have found that they can use NUDT14 as a biomarker to track disease progression and guide treatment decisions.

In addition to its potential as a drug target and biomarker, NUDT14 has also been shown to have a number of potential therapeutic applications in other areas. For example, NUDT14 has been shown to have anti-inflammatory effects, which could make it a potential treatment for a variety of inflammatory disorders. Additionally, NUDT14 has been shown to have neuroprotective effects, which could make it a potential treatment for a variety of neurological disorders.

While the potential applications of NUDT14 are significant, there are also potential drawbacks to its use as a drug target. One of the main challenges is the difficulty of targeting NUDT14 specifically, as it is expressed in a variety of tissues throughout the body. Additionally, the potential impact of NUDT14 on other physiological processes in the body could make it difficult to use it as a drug.

Overall, NUDT14 is a protein that has significant potential as a drug target and biomarker. While more research is needed to fully understand its effects and potential applications, its potential as a treatment for a variety of diseases makes it an important area of research.

Protein Name: Nudix Hydrolase 14

Functions: Hydrolyzes UDP-glucose to glucose 1-phosphate and UMP and ADP-ribose to ribose 5-phosphate and AMP. The physiological substrate is probably UDP-glucose. Poor activity on other substrates such as ADP-glucose, CDP-glucose, GDP-glucose and GDP-mannose

The "NUDT14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDT14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets